Annual CFF
$8.40 M
+$8.61 M+4204.00%
31 December 2023
Summary:
Inhibikase Therapeutics annual cash flow from financing activities is currently $8.40 million, with the most recent change of +$8.61 million (+4204.00%) on 31 December 2023. During the last 3 years, it has fallen by -$6.66 million (-44.21%). IKT annual CFF is now -79.55% below its all-time high of $41.09 million, reached on 31 December 2021.IKT Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$182.00 K
-$3.06 M-94.39%
30 September 2024
Summary:
Inhibikase Therapeutics quarterly cash flow from financing activities is currently $182.00 thousand, with the most recent change of -$3.06 million (-94.39%) on 30 September 2024. Over the past year, it has increased by +$181.90 thousand (+181900.00%). IKT quarterly CFF is now -99.56% below its all-time high of $41.47 million, reached on 30 June 2021.IKT Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$3.66 M
+$181.90 K+5.24%
30 September 2024
Summary:
Inhibikase Therapeutics TTM cash flow from financing activities is currently $3.66 million, with the most recent change of +$181.90 thousand (+5.24%) on 30 September 2024. Over the past year, it has dropped by -$4.89 million (-57.21%). IKT TTM CFF is now -93.47% below its all-time high of $55.98 million, reached on 30 September 2021.IKT TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IKT Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +4204.0% | +10000.0% | -57.2% |
| 3 y3 years | -44.2% | +508.7% | -93.5% |
| 5 y5 years | +2013.7% | +100.0% | +10000.0% |
IKT Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -79.5% | +4204.0% | -97.9% | +188.9% | -93.5% | +1884.8% |
| 5 y | 5 years | -79.5% | +2013.7% | -99.6% | +144.4% | -93.5% | +1884.8% |
| alltime | all time | -79.5% | +2013.7% | -99.6% | +144.4% | -93.5% | +1884.8% |
Inhibikase Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $182.00 K(-94.4%) | $3.66 M(+5.2%) |
| June 2024 | - | $3.24 M(+784.0%) | $3.47 M(+1699.6%) |
| Mar 2024 | - | $367.00 K(-365.7%) | $193.00 K(-97.7%) |
| Dec 2023 | $8.40 M(-4204.0%) | -$138.10 K(<-9900.0%) | $8.40 M(-1.6%) |
| Sept 2023 | - | $100.00(-100.3%) | $8.54 M(+0.0%) |
| June 2023 | - | -$36.00 K(-100.4%) | $8.54 M(-0.4%) |
| Mar 2023 | - | $8.58 M(>+9900.0%) | $8.58 M(-4289.0%) |
| Dec 2022 | -$204.80 K(-100.5%) | $0.00(0.0%) | -$204.80 K(0.0%) |
| Sept 2022 | - | $0.00(0.0%) | -$204.80 K(+17.1%) |
| June 2022 | - | $0.00(-100.0%) | -$174.90 K(-100.4%) |
| Mar 2022 | - | -$204.80 K(<-9900.0%) | $41.30 M(+0.5%) |
| Dec 2021 | $41.09 M | $0.00(-100.0%) | $41.09 M(-26.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | $29.90 K(-99.9%) | $55.98 M(+0.2%) |
| June 2021 | - | $41.47 M(<-9900.0%) | $55.88 M(+287.9%) |
| Mar 2021 | - | -$409.70 K(-102.8%) | $14.40 M(-4.4%) |
| Dec 2020 | $15.06 M(<-9900.0%) | $14.88 M(<-9900.0%) | $15.06 M(+8241.4%) |
| Sept 2020 | - | -$67.10 K(+2695.8%) | $180.60 K(-27.1%) |
| June 2020 | - | -$2400.00(-101.0%) | $247.70 K(-1.0%) |
| Mar 2020 | - | $250.10 K(>+9900.0%) | $250.10 K(-1196.9%) |
| Dec 2019 | -$22.80 K(-94.8%) | $0.00(0.0%) | -$22.80 K(0.0%) |
| Sept 2019 | - | $0.00(0.0%) | -$22.80 K(0.0%) |
| June 2019 | - | $0.00(-100.0%) | -$22.80 K(0.0%) |
| Mar 2019 | - | -$22.80 K | -$22.80 K |
| Dec 2018 | -$439.20 K | - | - |
FAQ
- What is Inhibikase Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual CFF year-on-year change?
- What is Inhibikase Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly CFF year-on-year change?
- What is Inhibikase Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics TTM CFF year-on-year change?
What is Inhibikase Therapeutics annual cash flow from financing activities?
The current annual CFF of IKT is $8.40 M
What is the all time high annual CFF for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual cash flow from financing activities is $41.09 M
What is Inhibikase Therapeutics annual CFF year-on-year change?
Over the past year, IKT annual cash flow from financing activities has changed by +$8.61 M (+4204.00%)
What is Inhibikase Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of IKT is $182.00 K
What is the all time high quarterly CFF for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly cash flow from financing activities is $41.47 M
What is Inhibikase Therapeutics quarterly CFF year-on-year change?
Over the past year, IKT quarterly cash flow from financing activities has changed by +$181.90 K (+181900.00%)
What is Inhibikase Therapeutics TTM cash flow from financing activities?
The current TTM CFF of IKT is $3.66 M
What is the all time high TTM CFF for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high TTM cash flow from financing activities is $55.98 M
What is Inhibikase Therapeutics TTM CFF year-on-year change?
Over the past year, IKT TTM cash flow from financing activities has changed by -$4.89 M (-57.21%)